ERBB2 and adenocarcinoma: In addition, the results of studies investigating the combination of immunotherapy, HER2-targeted therapy, and chemotherapy in HER2-positive resectable G/GEJ adenocarcinoma are still preliminary due to incomplete patient enrollment.